HYF
Immunoprecise Antibodies (HYFT) Q4 2024 Earnings
HYFT·Reported December 10, 2024·Before market open
Immunoprecise Antibodies reported Q4 2024 revenue of $4.4M, missed analyst consensus of $7.0M by $2.6M. Diluted EPS came in at $-0.09.
Revenue
$4.4Mmissed by $2.6M
Consensus: $7.0MDiluted EPS
$-0.09met estimate
Consensus: $-0.09
SEC Filings
Earnings release8-K not filed yet
Quarterly report10-Q / 10-K not filed yet
Filings will appear here once submitted to SEC EDGAR.
Q4 2024 Earnings FAQ
Common questions about Immunoprecise Antibodies's Q4 2024 earnings report.
Immunoprecise Antibodies (HYFT) reported Q4 2024 earnings on December 10, 2024 before market open.
Immunoprecise Antibodies reported revenue of $4.4M and diluted EPS of $-0.09 for Q4 2024.
Revenue missed the consensus estimate of $7.0M by $2.6M. EPS beat the consensus estimate of $-0.09 by $0.00.